,,welll,,,,,,,,,,,,,,,based on our history with RVX they have no idea about time lines or costs around these trials,,,,lets be honest,,back when we entered into BoM the end date was planned as December 2017,,,thats last year this time,,,and we were told way back when we were fully financed for the trial,,,but during the initial course of this trial the pre determined events number based on design started to change and the FA became non-essential and a thing of the past decidedly,,,meanwhile we were posting guesses as to event rate numbers from 2 ytears back ,,,,then we aimed for December 2018 and maybe its not going to be this month at all,,,,more likely into 2019,, early,,but could be sometime in the back end of the first half. All the time operating hand to mouth financially with our soul sold to the devil and getting news from the team of a deal at the very last hour. The financial end caused tremdous anxiety among us lifers at the time as I recall.

Back when the rate of events was determined to be of no significance to our probability of success now it seems to be somewhat in focus and creating a greater chance of success in the end if we stave off the predetermined events # as time passes. I am confused as heck as to what actually matters in this critical trial! And I dont think I am the only one. By extending BoM completion here, if that's what the latest info from RVX suggests, we also extend start dates for our other indications. So if true, my prediction is that we will be very lucky if we get any of these other trials into the clinic before 2019 is finished even if BoM is successful as its data is told to us to be of critical nature for the other trial designs. And data analysis seems to eat up lots of our precious time. jmo